Novartis faces securities fraud probe after dru... | Pluang

Pomerantz LLP has opened an investigation into Novartis and certain executives over potential securities fraud, after the company reported that its Phase III trial of del-desiran in myotonic dystrophy type 1 patients failed to show significant improvement. The announcement triggered a sharp market reaction: Novartis American Depositary Shares fell nearly 14% on September 8, 2026. The probe could affect investor confidence and may lead to legal actions if wrongdoing is established. As of October 1, 2026 at 21:12 WIB, Novartis AG shares on Pluang traded at USD 142.21, down 0.25% on the day, with market capitalization around $273.29 billion and a 3.32% dividend yield; order flow was 100% sell.